Summary

The market’s most troubling signal was not the whipsaw in equities but the simultaneous rise in bond yields and weakening dollar. After the White House paused most tariff increases for 90 days, the Dow rallied roughly 2,500 points and Paul Matteis saw the NASDAQ up 8%, yet company fundamentals barely entered investor conversations. Brad Loncar warned that capital may be leaving because the “rules of the game aren’t as durable as they used to be.”
Biotech’s catalyst bar has moved from suggestive evidence to data that truly disproves bear cases. Paul Matteis said investors no longer want “proof of principle”; they want “firmly proof of concept” or truly derisking results, while Tess Cameron argued that companies should favor complete, contextualized datasets over serial patient-level disclosures. Even explainable imperfections may receive “very little forgiveness” from investors outside the core holder base.
Private capital remains abundant, but depressed public comparables make new-company economics increasingly difficult. More than $35 billion has reportedly been raised by recently closed funds even as company formation sits at a greater-than-10-year low, yet Chris Garabedian stressed that venture valuations must be “reverse engineered” from eventual public valuations. The opportunity cost of private investing has also risen because beaten-down public equities now compete for the same capital.
Royalty financing could become an important substitute for closed IPO markets and scarce pharma partnerships. Brad said smaller royalty firms’ “phones are ringing off the hook,” with some now assuming development risk well before Phase 3 and investing directly in individual programs. They could also acquire negative-enterprise-value “zombie companies,” return cash to shareholders and retain residual assets—but Cameron cautioned that some capped royalty structures are “basically debt,” leaving companies responsible for repayment even when programs fail.
The FDA debate has split between institutional alarm and stock-specific optimism, while early operating evidence is already mixed. Eric Schmidt sees “severe damage” from leadership turnover, political interference and staff reductions; others think a more libertarian FDA could preserve or expand flexibility for severe rare diseases. Some sponsors report normal, timely interactions, but others describe conflicting feedback from junior reviewers, absent leadership, blocked escalation routes and meeting requests deferred until IND submission.
Pharmaceutical tariffs remain almost impossible to model, despite a defensible national-security case for domestic production. Loncar supported using America’s market power—the country is the industry’s “100-pound gorilla”—to bring manufacturing home, while Cameron argued that low-margin generics require a different approach because tariffs could worsen shortages. Announced multibillion-dollar US investments may help companies curry favor, but relocating facilities takes years and does not unwind legacy offshore IP structures.
Clinical readouts showed that expectation-setting and market positioning can matter almost as much as the data. Rhythm’s positive Phase 3 setmelanotide results in hypothalamic obesity beat a deliberately conservative hurdle and outperformed in a brutal tape; by contrast, Lexeo fell roughly 25–30% after apparently favorable Friedreich’s ataxia data, which Matteis viewed partly as selling into liquidity. Schmidt’s bleak summary of current catalysts: “There’s no such thing as good triggers… It’s bad and worse.”

Deep dive

1. Macro whiplash has displaced company fundamentals

Loncar’s warning centered on the bond market: volatility should ordinarily push capital toward US fixed income, yet yields rose as the dollar weakened. If investors are withdrawing simply because America feels less steady, “that would be a very bad sign” that ultimately reaches biotech.
The 90-day pause in most tariff increases produced a roughly 2,500-point Dow rally, followed quickly by renewed weakness. Matteis watched the NASDAQ climb 8% during a meeting and saw a hedge-fund investor feel compelled to race back to his desk—an unusually clean picture of markets overwhelming fundamental work.
Schmidt said incoming investor calls had almost nothing to do with company timelines, data or individual stocks. Everyone was instead becoming an amateur economist, political scientist or international-tax specialist because “literally the earth is shifting underneath our feet.”
The downside is structural, not merely mark-to-market: prolonged weakness could leave funds unable to continue, biotech companies unable to raise capital and sell-side shops unable to support their teams. Schmidt believes the industry is already shrinking and that “the shrinkage will be very dramatic” if current conditions persist.

2. Investors now demand catalysts that close bear cases

Matteis saw an initial flight toward commercial and late-stage companies after Peter Marks’s departure, but that positioning rapidly became consensus. For smaller stocks, a catalyst must now disprove one or two bear cases and create value—not merely demonstrate “proof of principle.”
Cameron argued that the definition of a catalyst has itself changed. Minor ambiguities can be heavily punished even when logically explainable, making sequential individual-patient disclosures particularly dangerous; companies should ideally release “pretty full, robust data sets” with enough context to address imperfections immediately.
Platform companies face a harsher financing loop: high cash requirements pressure the stock, the lower price increases implied dilution, and that dilution drives the stock lower again. Investors are therefore scrutinizing cash needs alongside clinical merit.
Close communication with top holders may help companies work through explainable flaws, Cameron said, but investors who are not deeply engaged with the story have little incentive to wait. In this tape, seemingly non-fundamental imperfections can become the entire trade.

3. Dry powder cannot solve broken venture exit math

Garabedian contrasted a greater-than-10-year low in company formation with more than $35 billion reportedly raised by funds that closed in recent years. Those managers have investment periods and must deploy capital, whether into new companies or later Series B, C and E rounds.
Bruce Booth’s case for building during the downturn makes sense over a long horizon, but Garabedian’s pushback was economic: venture valuations must be reverse engineered from public comparables. Weak listed-biotech valuations make it difficult for seed, Series A, crossover, IPO and public investors all to earn acceptable returns.
Discovery-stage companies face the hardest version of that equation because substantial capital must be spent before reaching the clinic. Private financings are still happening—including later-stage deals and a Series A exceeding $100 million—but investors remain anxious about what evidence will eventually produce an acquisition or IPO.
Cameron added that public-market drawdowns materially increased the opportunity cost of private capital. New companies beginning from scratch will therefore need a different profile from those formed several years ago, while asset in-licensing may remain more attractive than building platforms at inception.

4. Royalty capital is moving earlier—and could clear zombie companies

With the IPO window closed and major pharma deals uncertain, Loncar expects royalty financing to move “to the forefront over the next year or two.” Smaller firms are no longer limiting themselves to approved products or successful Phase 3 assets; some will accept development risk in exchange for future royalties.
His framing was asset-level investing: royalty firms can underwrite an individual program much as a hedge fund underwrites a stock, avoiding exposure to an entire company. After decades of attempts to create program-specific investment vehicles, the model may finally have sufficient capital and demand.
Royalty buyers could also acquire negative-enterprise-value companies, distribute their cash and retain early assets for later licensing. That gives boards a cleaner mechanism to wind down the “zombie companies” whose continued existence burdens the sector.
Cameron’s caveat is essential: structures vary between genuine asset-risk sharing and debt that is “basically” a royalty deal. In some deals the financier’s return is capped when the company wins, but repayment remains due when the company loses; management teams must inspect who actually bears downside.

5. The FDA is neither business as usual nor clearly broken

Schmidt said the agency remains “hanging in the balance.” Former FDA leaders including Janet Woodcock publicly opposed recent changes, while RFK Jr.’s comments about interfering with the Novavax COVID-vaccine process intensified concern over scientific independence.
Matteis separated the societal issue from the stock question. Although political interference is damaging, some investors think the new FDA could be more libertarian toward cell and gene therapy or severe rare diseases, leaving selected stocks mispriced because previously agreed flexible paths may survive.
Garabedian leaned cautiously optimistic, noting that frustration with delays, conservative guidance and excessive reliance on animal toxicology predates the current administration. More companies were already considering trials outside the US, so Makary’s initiative to reduce animal testing could signal useful pragmatism if translated into specific guidance.
Cameron agreed that the direction is encouraging because the FDA previously offered only “bring us the package and we’ll let you know if it’s okay.” Without concrete standards, sponsors rationally repeat conventional work; modernization requires actionable guidance plus experienced staff capable of implementing it.

6. Staff losses are degrading feedback before stopping reviews

Loncar’s small sample was reassuring: companies described normal, timely engagement, and Denali interacted with its CDER counterparts the day before and the week before filing for accelerated approval in Hunter syndrome. He acknowledged that the sample might not include a company whose counterpart had completely changed.
Schmidt reported a less comfortable picture: some sponsors found senior reviewers gone, junior reviewers issuing conflicting feedback and no experienced official available for escalation. One meeting lacked leadership despite extensive preparation, and another company was told not to pursue escalation because no one qualified was available in the ombudsman’s office.
Cameron described a mixed bag across her portfolio. One private company was denied a pre-IND meeting and told the FDA would review the material with the IND; her group is also weighing whether to request a Type A meeting amid the turmoil or pivot to the UK, Australia or elsewhere. The agency may be prioritizing which companies receive meetings and how much attention they receive.
Garabedian flagged a Pink Sheet source’s concern that appropriations could fall below the trigger needed for PDUFA, which requires user fees not to exceed 50% of total agency funding. He also said employees responsible for negotiating the user-fee program had left. Loncar separately highlighted project managers as often the “true liaison” with sponsors and said rumors that they might be among the cuts warrant watching.

7. Tariffs are a national-security argument without an investable model

Matteis’s honest non-answer was that investors do not know how to model tariffs across manufacturing locations, IP domiciles and possible calculation methods. Their clearer effect is more volatility in a high-beta sector: “How do you play defense around it?”
Schmidt argued tariffs apply primarily to commercial companies and may hurt biopharma less than industries with higher manufacturing costs. Large companies may wait because moving capacity takes at least three or four years, instead adjusting tax and manufacturing accounting when “we don’t even know what we’re solving for yet.”
Loncar supported pharmaceutical tariffs on national-security grounds and pointed to what he thought was a roughly $25 billion Novartis US commitment. America holds the negotiating leverage because it is overwhelmingly the industry’s largest market, while countries that attract manufacturing and IP often pay far less for the resulting drugs.
Cameron drew a sharp branded-versus-generic distinction: thin generic margins and concentrated offshore capacity already create shortages, so tariffs could worsen the most acute supply risk. Pharma investment announcements are politically smart, but some projects may have happened anyway, and moving factories cannot cheaply unwind IP structures established when US corporate tax was 35% rather than 21%.

8. Data rewarded Rhythm but punished Lexeo and left CNS questions open

Rhythm’s Phase 3 setmelanotide study in hypothalamic obesity was, for Matteis, a “management team masterclass” in expectation-setting. Management consistently established a conservative hurdle, then beat it; placebo patients—including some receiving GLP-1 drugs—continued gaining weight over a year, reinforcing the population’s unmet need.
Lexeo’s Friedreich’s ataxia update contained noisy frataxin and variable-baseline LVMI data, but Matteis saw no major surprise and considered the results favorable. The 25–30% decline looked partly like selling into liquidity, amplified by a broader “shoot first, ask questions later” reckoning over gene-therapy commercialization, terminal value and Sarepta’s DMD setback.
Alzheon’s APOLLOE4 Phase 3 study was not statistically significant overall. A prespecified mild-cognitive-impairment subgroup showed separation on CDR-SB, which Cameron believed was not statistically significant, leaving a genuine question over whether the rationale supports moving forward in a narrower group.
Roche’s brain-shuttle trontinemab continued to suggest faster plaque clearance with lower ARIA; after a cerebral hemorrhage prompted tighter enrollment criteria, no further such cases were reported. Cameron said the 3.6-mg high-dose group appeared to have no cases of ARIA. Amgen’s CD19 antibody in myasthenia gravis also improved from roughly 1.88 placebo-adjusted MG-ADL points initially to −2.8 at 52 weeks, making it more competitive than its first disclosure implied.

Trump vs Harvard, Nvidia export controls, how DEI killed Hollywood with Tim Dillon Episode 137 - April 4, 2025